Quinoline compound KM11073 enhances BMP-2-dependent osteogenic differentiation of C2C12 cells via activation of p38 signaling and exhibits in vivo bone forming activity

PloS One
Seung-hwa BaekSeong Hwan Kim

Abstract

Recombinant human bone morphogenetic protein (rhBMP)-2 has been approved by the FDA for clinical application, but its use is limited due to high cost and a supra-physiological dose for therapeutic efficacy. Therefore, recent studies have focused on the generation of new therapeutic small molecules to induce bone formation or potentiate the osteogenic activity of BMP-2. Here, we show that [4-(7-chloroquinolin-4-yl) piperazino][1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]methanone (KM11073) strongly enhances the BMP-2-stimulated induction of alkaline phosphatase (ALP), an early phase biomarker of osteoblast differentiation, in bi-potential mesenchymal progenitor C2C12 cells. The KM11073-mediated ALP induction was inhibited by the BMP antagonist noggin, suggesting that its osteogenic activity occurs via BMP signaling. In addition, a pharmacological inhibition study suggested the involvement of p38 activation in the osteogenic action of KM11073 accompanied by enhanced expression of BMP-2, -6, and -7 mRNA. Furthermore, the in vivo osteogenic activity of KM11073 was confirmed in zebrafish and mouse calvarial bone formation models, suggesting the possibility of its single use for bone formation. In conclusion, the combination of rhBM...Continue Reading

References

Mar 18, 1996·Biochemical and Biophysical Research Communications·A YamaguchiS Yoshiki
Jan 1, 1997·Mechanisms of Development·M NikaidoN Ueno
Dec 17, 1998·Journal of Biomedical Materials Research·J O HollingerJ Wozney
Sep 1, 2000·Science·G A Rodan, T J Martin
Jan 29, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·C A LuppenM L Bouxsein
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 9, 2002·Clinical Orthopaedics and Related Research·Alexandre Valentin-OpranGerard E Riedel
Aug 5, 2003·Nature Reviews. Genetics·Steven L Teitelbaum, F Patrick Ross
Aug 20, 2003·The Journal of Bone and Joint Surgery. American Volume·Sylke HasselPetra Knaus
Aug 20, 2003·The Journal of Bone and Joint Surgery. American Volume·Hongwei ChengTong-Chuan He
Sep 2, 2003·Nature Biotechnology·Misako Nakashima, A Hari Reddi
Nov 5, 2003·Experimental Cell Research·Ulrich NöthRocky S Tuan
Jul 21, 2004·Gene Expression Patterns : GEP·Maria Vega FloresShannon Fisher
Jun 7, 2005·Cytokine & Growth Factor Reviews·Howard Seeherman, John M Wozney
Nov 2, 2005·Journal of Bone and Mineral Metabolism·Yukio NakamuraKunio Takaoka
Mar 7, 2007·Current Topics in Developmental Biology·I R Garrett
Jul 20, 2007·International Orthopaedics·William F McKayJeffrey M Badura
Oct 27, 2007·International Orthopaedics·Andrew P WhiteMichael D McKee
Mar 5, 2008·Journal of Biomedical Materials Research. Part a·Eiki YamachikaToshio Sugahara
Jan 24, 2009·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Nan LiHenry H Roehl
Mar 3, 2009·Journal of Bone and Mineral Metabolism·Kazushi TakayamaKunio Takaoka
Apr 7, 2011·Amino Acids·Soon Nam KimSeong Hwan Kim
Jul 7, 2011·The Spine Journal : Official Journal of the North American Spine Society·Eugene J CarrageeBradley K Weiner
Jul 24, 2012·Regenerative Medicine·Kevin W-H LoCato T Laurencin
Mar 26, 2013·PloS One·Karen VrijensMartine F Roussel

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
protein assay

Software Mentioned

Image J

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.